10 results on '"Zaritsky, Joshua"'
Search Results
2. Poor adherence to early childhood blood pressure measurement guidelines in a large pediatric healthcare system
- Author
-
Shah, Lokesh, Hossain, Jobayer, Xie, Shirlly, and Zaritsky, Joshua
- Published
- 2019
- Full Text
- View/download PDF
3. Successful treatment of calcific uremic arteriolopathy in a pediatric dialysis patient
- Author
-
Amin, Nimisha, Gonzalez, Elsa, Lieber, Michael, Salusky, Isidro B., and Zaritsky, Joshua J.
- Subjects
Medicine & Public Health ,Pediatrics ,Calciphylaxis ,Sodium thiosulfate ,Hyperbaric oxygen ,Wegener’s granulomatosis - Abstract
Calcific uremic arteriolopathy (CUA) is a rare, life-threatening disease, typically affecting patients with end-stage renal disease. It is characterized by widespread vascular calcification, endothelial fibrosis and end-organ ischemia. The mortality rate is high with infection and sepsis being the most common causes of death. Common therapies include restoration of calcium and phosphorous homeostasis, wound care and pain control. Although soft tissue calcification is a known complication in children with advanced renal disease, the incidence of CUA in pediatrics remains unknown. Additionally, current literature regarding its management in pediatric patients is lacking. We report the case of a 17-year-old African–American male patient with end-stage renal disease secondary to Wegener’s granulomatosis who developed CUA after 3 years on peritoneal dialysis. Treatment with sodium thiosulfate (STS) and hyperbaric oxygen (HBO) therapy alone was ineffective, forcing the patient to undergo bilateral below the-knee-amputation (BKA) 5 months after presentation. It was not until peritoneal dialysis had been changed to daily hemodialysis, while continuing STS and HBO therapy, that the patient demonstrated complete resolution of CUA on repeat bone scan. Based on these findings, and the extremely high mortality rate associated with this disease, CUA management requires early and aggressive intervention with multi-faceted therapy, including prompt conversion from peritoneal dialysis to hemodialysis, STS infusions and hyperbaric oxygen therapy.
- Published
- 2010
4. Sevelamer carbonate increases serum bicarbonate in pediatric dialysis patients
- Author
-
Gonzalez, Elsa, Schomberg, John, Amin, Nimisha, Salusky, Isidro B., and Zaritsky, Joshua
- Subjects
Medicine & Public Health ,Pediatrics ,Sevelamer HCl ,Sevelamer carbonate ,Metabolic acidosis ,Pediatric dialysis patients - Abstract
Sevelamer hydrochloride (HCl), a calcium-free phosphate binder, is increasingly used due to concerns related to calcium exposure and the development of vascular calcifications. However, a common side effect of sevelamer HCl, metabolic acidosis, is particularly concerning in children, as it can contribute to poor growth. Sevelamer carbonate is now available and has been shown to increase serum bicarbonate in adult patients. We conducted a prospective single-center study of pediatric dialysis patients comparing serum bicarbonate before and 3 months after a switch from sevelamer HCl to sevelamer carbonate. Inclusion criteria were a minimum of 3 months of dialysis therapy and either a serum bicarbonate
- Published
- 2010
5. A biphasic dialytic strategy for the treatment of neonatal hyperammonemia
- Author
-
Hanudel, Mark, Avasare, Sonal, Tsai, Eileen, Yadin, Ora, and Zaritsky, Joshua
- Published
- 2014
- Full Text
- View/download PDF
6. Global Variation of Nutritional Status in Children Undergoing Chronic Peritoneal Dialysis: A Longitudinal Study of the International Pediatric Peritoneal Dialysis Network
- Author
-
Schaefer, Franz, Benner, Laura, Borzych-Duzalka, Dagmara, Zaritsky, Joshua, Xu, Hong, Rees, Lesley, Antonio, Zenaida L., Serdaroglu, Erkin, Hooman, Nakysa, Patel, Hiren, Sever, Lale, Vondrak, Karel, Flynn, Joseph, Rebori, Anabella, Wong, William, Holtta, Tuula, Yildirim, Zeynep Yuruk, Ranchin, Bruno, Grenda, Ryszard, Testa, Sara, Drozdz, Dorota, Szabo, Attila J., Eid, Loai, Basu, Biswanath, Vitkevic, Renate, Wong, Cynthia, Pottoore, Stephen J., Mueller, Dominik, Dusunsel, Ruhan, Celedon, Claudia Gonzalez, Fila, Marc, Sartz, Lisa, Sander, Anja, Warady, Bradley A., Adragna, M., Coccia, P. A., Suarez, A., Valles, P. G., Salim, R., Alconcher, L., Arbeiter, K., van Hoeck, K., Koch, V, Feber, J., Harvey, E., White, C., Valenzuela, M., Villagra, J., Cano, F., Contreras, M. A., Vogel, A., Zambrano, P., Hevia, P., Chiu, M. C., Ding, Jie, Vanegas, J. J., Higuita, L. M., Roussey, G., Ulinski, T., Krid, S., Fischbach, M., Harambat, J., Samaille, Ch, Buescher, R., Oh, J., Pape, L., John, U., Klaus, G., Billing, H., Stafanidis, C., Papachristou, F., Bagga, A., Kanitkar, M., Sinha, R., Sethi, S., Verrinam, E., Vidal, E., Leozappa, G., Landau, D., Paik, K. H., Bilal, A., Sahpazova, E., Lim, Y. N., Barbosa, L. Sanchez, Groothoff, J. W., Konijenberg, Y., Silva, Y., Al Ryami, M., Munarriz, R. Loza, Leszepanska, B., Szczepanska, M., Brumariu, O., Kari, J., Kruscic, D., Yap, H. K., Ariceta, G., Aguirre, M., Santos, F., Niwhiska-Faryna, B., Bayazit, A., Bakkaloglu, C. A. S., Bakkaloglu, S., Bilge, I, Yavascan, O., Mir, S., Simkova, Eva, Christian, M., Greenbaum, L., Neu, A., Askenazi, D., Al-Akash, A., Swartz, S., Brophy, P., Rheault, M., Pradhan, M., Pediatric surgery, Amsterdam Reproduction & Development (AR&D), Çukurova Üniversitesi, Büscher (R.), Rainer (Beitragende*r), Paediatric Nephrology, AGEM - Inborn errors of metabolism, APH - Methodology, APH - Quality of Care, ARD - Amsterdam Reproduction and Development, Ege Üniversitesi, Int Pediat Peritoneal Dial Network, Children's Hospital, Clinicum, and HUS Children and Adolescents
- Subjects
Male ,0301 basic medicine ,Pediatric Obesity ,Longitudinal study ,Pediatrics ,medicine.medical_treatment ,Medizin ,lcsh:Medicine ,Overweight ,DISEASE ,0302 clinical medicine ,Risk Factors ,Prevalence ,Longitudinal Studies ,Registries ,Child ,lcsh:Science ,RISK ,2. Zero hunger ,OUTCOMES ,Multidisciplinary ,3. Good health ,Europe ,OBESITY ,Child, Preschool ,GROWTH ,Female ,medicine.symptom ,Underweight ,Peritoneal Dialysis ,Engineering sciences. Technology ,medicine.medical_specialty ,Asia ,Adolescent ,Nutritional Status ,Article ,Peritoneal dialysis ,03 medical and health sciences ,Enteral Nutrition ,Thinness ,medicine ,Humans ,Dialysis ,business.industry ,MORTALITY ,lcsh:R ,Infant ,nutritional and metabolic diseases ,medicine.disease ,Obesity ,BODY-MASS INDEX ,030104 developmental biology ,3121 General medicine, internal medicine and other clinical medicine ,Kidney Failure, Chronic ,lcsh:Q ,Americas ,business ,Body mass index ,030217 neurology & neurosurgery ,Kidney disease - Abstract
WOS: 000461762600003, PubMed ID: 30894599, While children approaching end-stage kidney disease (ESKD) are considered at risk of uremic anorexia and underweight they are also exposed to the global obesity epidemic. We sought to investigate the variation of nutritional status in children undergoing chronic peritoneal dialysis (CPD) around the globe. The distribution and course of body mass index (BMI) standard deviation score over time was examined prospectively in 1001 children and adolescents from 35 countries starting CPD who were followed in the International Pediatric PD Network (IPPN) Registry. The overall prevalence of underweight, and overweight/obesity at start of CPD was 8.9% and 19.7%, respectively. Underweight was most prevalent in South and Southeast Asia (20%), Central Europe (16.7%) and Turkey (15.2%), whereas overweight and obesity were most common in the Middle East (40%) and the US (33%). BMI SDS at PD initiation was associated positively with current eGFR and gastrostomy feeding prior to PD start. Over the course of PD BMI SDS tended to increase on CPD in underweight and normal weight children, whereas it decreased in initially overweight patients. In infancy, mortality risk was amplified by obesity, whereas in older children mortality was markedly increased in association with underweight. Both underweight and overweight are prevalent in pediatric ESKD, with the prevalence varying across the globe. Late dialysis start is associated with underweight, while enteral feeding can lead to obesity. Nutritional abnormalities tend to attenuate with time on dialysis. Mortality risk appears increased with obesity in infants and with underweight in older children., International Society for Peritoneal Dialysis; Baxter Health Care; Fresenius Medical Care, The authors gratefully acknowledge the support by the International Society for Peritoneal Dialysis, Baxter Health Care, and Fresenius Medical Care. We also appreciate the continued dedicated support of the IPPN by the medical and nursing staff in all collaborating centers.
- Published
- 2019
7. Continued reduction in peritonitis rates in pediatric dialysis centers: results of the Standardizing Care to Improve Outcomes in Pediatric End Stage Renal Disease (SCOPE) Collaborative.
- Author
-
Neu, Alicia M., Richardson, Troy, De Souza, Heidi Gruhler, Mahon, Allison Redpath, Keswani, Mahima, Zaritsky, Joshua, Munshi, Raj, Swartz, Sarah, Sethna, Christine B., Somers, Michael J. G., and Warady, Bradley A.
- Subjects
MEDICAL quality control ,PERITONITIS ,CONFIDENCE intervals ,PREVENTION of communicable diseases ,PEDIATRICS ,DIALYSIS catheters ,MEDICAL protocols ,HEMODIALYSIS facilities ,LOGISTIC regression analysis ,ODDS ratio ,CHILDREN - Abstract
Background: In its first 3 years, the Standardizing Care to Improve Outcomes in Pediatric End Stage Renal Disease (SCOPE) Collaborative demonstrated a statistically significant increase in the likelihood of compliance with a standardized follow-up care bundle and a significant reduction in peritonitis. We sought to determine if compliance with care bundles and low peritonitis rates could be sustained in centers continuously participating for 84 months. Methods: Centers that participated from collaborative launch through the 84-month study period and provided pre-launch peritonitis rates were included. Children on maintenance peritoneal dialysis were eligible for enrollment. Changes in bundle compliance were assessed using a logistic regression model or a generalized linear mixed model (GLMM). Changes in average annualized peritonitis rates over time were modeled using GLMMs. Results: Nineteen centers contributed 1055 patients with 1268 catheters and 17,247 follow-up encounters. The likelihood of follow-up compliance increased significantly over the study period (OR 1.05 95% confidence interval (CI) 1.03, 1.07; p < 0.001). Centers achieved ≥ 80% follow-up bundle compliance by 28 months and maintained a mean compliance of 84% between 28 and 84 months post-launch. Average monthly peritonitis rates decreased from 0.53 (95% CI 0.37, 0.70) infections per patient-year pre-launch to 0.30 (95% CI 0.23, 0.43) at 84 months post-launch, p < 0.001. Conclusions: Centers participating in the SCOPE Collaborative for 84 months achieved and maintained a high level of compliance with a standardized follow-up care bundle and demonstrated a significant and continued reduction in average monthly peritonitis rates. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
8. LDL-apheresis-induced remission of focal segmental glomerulosclerosis recurrence in pediatric renal transplant recipients.
- Author
-
Shah, Lokesh, Hooper, David K., Okamura, Daryl, Wallace, Dean, Moodalbail, Divya, Gluck, Caroline, Koziell, Ania, and Zaritsky, Joshua J.
- Subjects
METHYLPREDNISOLONE ,CHILDREN'S hospitals ,COMBINED modality therapy ,CREATININE ,GLOMERULAR filtration rate ,HEMAPHERESIS ,KIDNEY transplantation ,LOW density lipoproteins ,MEDICAL protocols ,PEDIATRICS ,POSTOPERATIVE period ,PROTEINURIA ,TRANSPLANTATION of organs, tissues, etc. ,DISEASE relapse ,TREATMENT effectiveness ,DISEASE remission ,FOCAL segmental glomerulosclerosis ,THERAPEUTICS - Abstract
Background: Focal segmental glomerulosclerosis (FSGS) in pediatric patients is typically difficult to treat and will progress to end-stage renal disease (ESRD) in about 10% of cases. Following kidney transplantation, FSGS can recur in up to 56% of renal allografts—with a near 100% recurrence in subsequent transplants. Methods: Four different pediatric centers across the USA and the UK employed a protocol using LDL-apheresis (LDL-A) and pulse solumedrol to treat recurrent FSGS after transplantation in seven patients. All the patients included in this series demonstrated immediate, or early, recurrence of FSGS, which clinically presented as nephrotic-range proteinuria within hours to days after implantation of the kidney. Results: All patients experienced reductions in urinary protein to creatinine ratios resulting in partial or complete remission. All patients demonstrated improvements in their estimated GFRs at their most recent follow-up since LDL-A discontinuation. Conclusions: This case series describes the successful treatment, across four different pediatric centers, of seven pediatric patients with recurrent post-transplant FSGS using the Liposorber® LA-15 in combination with pulse solumedrol. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
9. Pharmacokinetics of ferric pyrophosphate citrate administered via dialysate and intravenously to pediatric patients on chronic hemodialysis.
- Author
-
Pratt, Raymond D., Grimberg, Sarah, Zaritsky, Joshua J., and Warady, Bradley A.
- Subjects
CITRATES ,HEMODIALYSIS ,INTRAVENOUS therapy ,IRON ,IRON compounds ,IRON deficiency anemia ,PEDIATRICS ,PHARMACOKINETICS ,PHOSPHORIC acid - Abstract
Background: Iron deficiency is a common cause of anemia in pediatric patients with hemodialysis-dependent chronic kidney disease (CKD-5HD). Ferric pyrophosphate citrate (FPC, Triferic®) donates iron directly to transferrin, bypassing the reticuloendothelial system and avoiding iron sequestration. Administration of FPC via dialysate or intravenously (IV) may provide a suitable therapeutic option to current IV iron preparations for these patients.Methods: The pharmacokinetics and safety of FPC administered via dialysate and IV to patients aged < 6 years (n = 3), 6 to < 12 years (n = 4), and 12 to <18 years (n = 15) were investigated in a multicenter, open-label, two-period, single-dose study. FPC (0.07 mg iron/kg) was infused IV into the venous blood return line during hemodialysis session no. 1. FPC iron was added to bicarbonate concentrate to deliver 2 μM (110 μg/L) iron via dialysate during hemodialysis session no. 2.Results: Mean serum total iron concentrations peaked 3 to 4 h after administration via dialysate and 2 to 4 h after IV administration and returned to baseline by 10 h after the start of hemodialysis for both routes. Iron exposure was greater after administration via dialysate than after IV administration. The absolute amount of absorbed iron after administration via dialysate roughly doubled with increasing age, but the weight-normalized amount of absorbed iron was relatively constant across age groups (~ 0.06-0.10 mg/kg). FPC was well tolerated in the small number of patients studied.Conclusions: FPC iron can be administered to pediatric patients with CKD-5HD via dialysate or by the IV route. Further study of FPC administered to maintain hemoglobin concentration is indicated. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
10. High-resolution, whole-body vascular imaging with ferumoxytol as an alternative to gadolinium agents in a pediatric chronic kidney disease cohort.
- Author
-
Nayak, Anjali, Luhar, Aarti, Hanudel, Mark, Gales, Barbara, Hall, Theodore, Finn, J., Salusky, Isidro, and Zaritsky, Joshua
- Subjects
ANGIOGRAPHY ,CHRONIC kidney failure ,DIAGNOSTIC imaging ,MAGNETIC resonance imaging ,MINERALS ,PEDIATRICS ,CONTRAST media ,DESCRIPTIVE statistics - Abstract
Background: Exposure to gadolinium-based contrast agents (GBCA) in patients with chronic kidney disease (CKD) has been associated with the development of a potentially fatal disorder, nephrogenic systemic fibrosis (NSF). Although contrast-enhanced computed tomography (CT) is an alternative to magnetic resonance imaging (MRI), it carries the risk of radiation exposure and further reduction of residual renal function. Therefore we sought to assess the feasibility of ferumoxytol as an alternative to GBCA for contrast-enhanced MR angiography (MRA) in a pediatric cohort with CKD. Ferumoxytol is a parenteral iron supplement that contains ultrasmall superparamagnetic iron oxide (USPIO) and is a potent relaxivity agent for MRI. Methods: We describe the MRI findings in ten pediatric patients who needed detailed vascular mapping. Ferumoxytol (4 mg/kg) was administered intravenously for contrast-enhanced MRA. The patients tolerated the procedure without complications. Results: Resulting studies were highly diagnostic and were pivotal in guiding patient management. The images were notable for clear delineation of multiple vascular occlusions. Conclusions: Given the concerns associated with the use of GBCAs in renal failure, ferumoxytol is an excellent alternative contrast agent in pediatric end stage renal disease (ESRD) patients. Future studies are needed in order to further evaluate safety and efficacy of ferumoxytol in this patient population. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.